(RTTNews) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, raised its adjusted earnings guidance for the full-year 2025.
For fiscal 2025, Merck now projects adjusted earnings in a range of $8.93 to $8.98 per share on sales between $64.5 billion and $65.0 billion. Previously, the company expected $8.87 to $8.97 per share on sales between $64.3 billion and $65.3 billion.
On average, analysts polled expect the company to report earnings of $8.89 per share on sales of $64.81 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
